Histone deacetylase inhibitors potentiate vesicular stomatitis virus oncolysis in prostate cancer cells by modulating NF-κB-dependent autophagy

Journal of Virology

Volumn 88, Issue 5, 2014, Pages 2927-2940

  Shulak, Laura ^a   Beljanski, Vladimir ^b   Chiang, Cindy ^b   Dutta, Sucharita M ^c   Van Grevenynghe, Julien ^a   Belgnaoui, S Mehdi ^a   Nguyên, Thi Lien Anh ^a   Di Lenardo, Thomas ^a   Semmes, O John ^c   Lin, Rongtuan ^a   Hiscott, John ^b  

^a MCGILL UNIVERSITY   (Canada)

^b Vaccine and Gene Therapy Institute of Florida   (United States)

^c EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLADENINE; AUTOPHAGY PROTEIN 5; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; ONCOLYTIC VIRUS; TRANSCRIPTION FACTOR RELA; TRANSCRIPTOME; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; BIOINFORMATICS; CELL KILLING; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME INDUCTION; ENZYME REPRESSION; GENE EXPRESSION; GENE TARGETING; HISTONE ACETYLATION; HUMAN; HUMAN CELL; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RNA ANALYSIS; SIGNAL TRANSDUCTION; UPREGULATION; VESICULAR STOMATITIS VIRUS; VIRUS REPLICATION;

ACETYLATION; ANIMALS; AUTOPHAGY; CELL LINE, TUMOR; CHROMATIN; CLUSTER ANALYSIS; GENE KNOCKDOWN TECHNIQUES; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MALE; MICE; NF-KAPPA B; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PROSTATIC NEOPLASMS; PROTEIN BINDING; PROTEIN TRANSPORT; TRANSCRIPTION FACTOR RELA; TRANSCRIPTOME; VESICULAR STOMATITIS INDIANA VIRUS; VIRUS REPLICATION;

EID: 84896727159     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03406-13     Document Type: Article

References (60)

1. Rowan K. 2010. Oncolytic viruses move forward in clinical trials. J. Natl. Cancer Inst. 102:590-595. http://dx.doi.org/10.1093/jnci/djq165.
2. Breitbach CJ, Burke J, Jonker D, Stephenson J, Haas AR, Chow LQ, Nieva J, Hwang TH, Moon A, Patt R, Pelusio A, Le Boeuf F, Burns J, Evgin L, De Silva N, Cvancic S, Robertson T, Je JE, Lee YS, Parato K, Diallo JS, Fenster A, Daneshmand M, Bell JC, Kirn DH. 2011. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 477:99-102. http://dx.doi.org/10.1038/nature10358.
3. Russell SJ, Peng KW, Bell JC. 2012. Oncolytic virotherapy. Nat. Biotechnol. 30:658-670. http://dx.doi.org/10.1038/nbt.2287.
4. Hastie E, Grdzelishvili VZ. 2012. Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer. J. Gen. Virol. 93:2529-2545. http://dx.doi.org/10.1099/vir.0.046672-0.
5. Cary ZD, Willingham MC, Lyles DS. 2011. Oncolytic vesicular stomatitis virus induces apoptosis in U87 glioblastoma cells by a type II death receptor mechanism and induces cell death and tumor clearance in vivo. J. Virol. 85:5708-5717. http://dx.doi.org/10.1128/JVI.02393-10.
6. Pearce AF, Lyles DS. 2009. Vesicular stomatitis virus induces apoptosis primarily through Bak rather than Bax by inactivating Mcl-1 and Bcl-XL. J. Virol. 83:9102-9112. http://dx.doi.org/10.1128/JVI.00436-09.
7. Gaddy DF, Lyles DS. 2005. Vesicular stomatitis viruses expressing wild-type or mutant M proteins activate apoptosis through distinct pathways. J. Virol. 79: 4170-4179. http://dx.doi.org/10.1128/JVI.79.7.4170-4179.2005.
8. Goubau D, Deddouche S, Reis ESC. 2013. Cytosolic sensing of viruses. Immunity 38:855-869. http://dx.doi.org/10.1016/j.immuni.2013.05.007.
9. Mullen JT, Tanabe KK. 2002. Viral oncolysis. Oncologist 7:106-119. http://dx.doi.org/10.1634/theoncologist.7-2-106.
10. Kelly E, Russell SJ. 2007. History of oncolytic viruses: genesis to genetic engineering. Mol. Ther. 15:651-659. http://dx.doi.org/10.1038/sj.mt.6300108.
11. Sinkovics JG, Horvath JC. 2008. Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers. Arch. Immunol. Ther. Exp. (Warsz) 56(Suppl 1):3s-59s. http://dx.doi.org/10.1007/s00005-008-0047-9.
12. Kurisetty VV, Heiber J, Myers R, Pereira GS, Goodwin JW, Federspiel MJ, Russell SJ, Peng KW, Barber G, Merchan JR. 2013. Preclinical safety and activity of recombinant VSV-IFN-beta in an immunocompetent model of squamous cell carcinoma of the head and neck. Head Neck. http://dx.doi.org/10.1002/hed.23502.
13. Naik S, Nace R, Barber GN, Russell SJ. 2012. Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-beta. Cancer Gene Ther. 19:443-450. http://dx.doi.org/10 .1038/cgt.2012.14.
14. Stojdl DF, Lichty BD, ten Oever BR, Paterson JM, Power AT, Knowles S, Marius R, Reynard J, Poliquin L, Atkins H, Brown EG, Durbin RK, Durbin JE, Hiscott J, Bell JC. 2003. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4:263-275. http://dx.doi.org/10.1016/S1535-6108(03)00241-1.
15. Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N, Bell JC. 2000. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat. Med. 6:821-825. http://dx.doi .org/10.1038/77558.
16. Faria PA, Chakraborty P, Levay A, Barber GN, Ezelle HJ, Enninga J, Arana C, van Deursen J, Fontoura BM. 2005. VSV disrupts the Rae1/ mrnp41 mRNA nuclear export pathway. Mol. Cell 17:93-102. http://dx .doi.org/10.1016/j.molcel.2004.11.023.
17. Barber GN. 2005. VSV-tumor selective replication and protein translation. Oncogene 24:7710-7719. http://dx.doi.org/10.1038/sj.onc.1209042.
18. Russell SJ, Peng KW. 2007. Viruses as anticancer drugs. Trends Pharmacol. Sci. 28:326-333. http://dx.doi.org/10.1016/j.tips.2007.05.005.
19. Nguyen TL, Abdelbary H, Arguello M, Breitbach C, Leveille S, Diallo JS, Yasmeen A, Bismar TA, Kirn D, Falls T, Snoulten VE, Vanderhyden BC, Werier J, Atkins H, Vähä-Koskela MJ, Stojdl DF, Bell JC, Hiscott J. 2008. Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proc. Natl. Acad. Sci. U. S. A. 105:14981-14986. http://dx.doi.org/10 .1073/pnas.0803988105.
20. Ahmed M, Cramer SD, Lyles DS. 2004. Sensitivity of prostate tumors to wild type and M protein mutant vesicular stomatitis viruses. Virology 330:34-49. http://dx.doi.org/10.1016/j.virol.2004.08.039.
21. Nguyen TL, Wilson MG, Hiscott J. 2010. Oncolytic viruses and histone deacetylase inhibitors-a multi-pronged strategy to target tumor cells. Cytokine Growth Factor Rev. 21:153-159. http://dx.doi.org/10.1016/j .cytogfr.2010.03.002.
22. Glozak MA, Seto E. 2007. Histone deacetylases and cancer. Oncogene 26:5420-5432. http://dx.doi.org/10.1038/sj.onc.1210610.
23. Katsura T, Iwai S, Ota Y, Shimizu H, Ikuta K, Yura Y. 2009. The effects of trichostatin A on the oncolytic ability of herpes simplex virus for oral squamous cell carcinoma cells. Cancer Gene Ther. 16:237-245. http://dx .doi.org/10.1038/cgt.2008.81.
24. Pei XY, Dai Y, Grant S. 2004. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin. Cancer Res. 10: 3839-3852. http://dx.doi.org/10.1158/1078-0432.CCR-03-0561.
25. Suliman BA, Xu D, Williams BR. 2012. HDACi: molecular mechanisms and therapeutic implications in the innate immune system. Immunol. Cell Biol. 90:23-32. http://dx.doi.org/10.1038/icb.2011.92.
26. Laurenzana A, Balliu M, Cellai C, Romanelli MN, Paoletti F. 2013. Effectiveness of the histone deacetylase inhibitor (S)-2 against LNCaP and PC3 human prostate cancer cells. PLoS One 8:e58267. http://dx.doi.org/10.1371/journal.pone.0058267.
27. Hwang JJ, Kim YS, Kim T, Kim MJ, Jeong IG, Lee JH, Choi J, Jang S, Ro S, Kim CS. 2012. A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL. Invest. New Drugs 30:1434-1442. http://dx.doi.org/10 .1007/s10637-011-9718-1.
28. Kortenhorst MS, Zahurak M, Shabbeer S, Kachhap S, Galloway N, Parmigiani G, Verheul HM, Carducci MA. 2008. A multiple-loop, double-cube microarray design applied to prostate cancer cell lines with variable sensitivity to histone deacetylase inhibitors. Clin. Cancer Res. 14: 6886-6894. http://dx.doi.org/10.1158/1078-0432.CCR-08-0119.
29. Xu W, Ngo L, Perez G, Dokmanovic M, Marks PA. 2006. Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. Proc. Natl. Acad. Sci. U. S. A. 103:15540-15545. http://dx.doi.org/10.1073/pnas.0607518103.
30. Gammoh N, Lam D, Puente C, Ganley I, Marks PA, Jiang X. 2012. Role of autophagy in histone deacetylase inhibitor-induced apoptotic and nonapoptotic cell death. Proc. Natl. Acad. Sci. U. S. A. 109:6561-6565. http://dx.doi.org/10.1073/pnas.1204429109.
31. Lee YJ, Won AJ, Lee J, Jung JH, Yoon S, Lee BM, Kim HS. 2012. Molecular mechanism of SAHA on regulation of autophagic cell death in tamoxifen-resistant MCF-7 breast cancer cells. Int. J. Med. Sci. 9:881-893. http://dx.doi.org/10.7150/ijms.5011.
32. ChoiAM,RyterSW,Levine B. 2013. Autophagy inhumanhealth and disease. N. Engl. J. Med. 368:651-662. http://dx.doi.org/10.1056/NEJMra1205406.
33. Kirkegaard K. 2009. Subversion of the cellular autophagy pathway by viruses. Curr. Top. Microbiol. Immunol. 335:323-333. http://dx.doi.org/10.1007/978-3-642-00302-8_16.
34. Kudchodkar SB, Levine B. 2009. Viruses and autophagy. Rev. Med. Virol. 19:359-378. http://dx.doi.org/10.1002/rmv.630.
35. Dreux M, Chisari FV. 2010. Viruses and the autophagy machinery. Cell Cycle 9:1295-1307. http://dx.doi.org/10.4161/cc.9.7.11109.
36. Meng S, Xu J, Wu Y, Ding C. 2013. Targeting autophagy to enhance oncolytic virus-based cancer therapy. Exp. Opin. Biol. Ther. 13:863-873. http://dx.doi.org/10.1517/14712598.2013.774365.
37. Schulze J, Weber K, Baranowsky A, Streichert T, Lange T, Spiro AS, Albers J, Seitz S, Zustin J, Amling M, Fehse B, Schinke T. 2012. p65-Dependent productionof interleukin-1betabyosteolytic prostatecancercellscausesaninduction of chemokine expression in osteoblasts. Cancer Lett. 317:106-113. http://dx.doi .org/10.1016/j.canlet.2011.11.016.
38. Belgnaoui SM, Paz S, Samuel S, Goulet ML, Sun Q, Kikkert M, Iwai K, Dikic I, Hiscott J, Lin R. 2012. Linear ubiquitination of NEMO negatively regulates the interferon antiviral response through disruption of the MAVS-TRAF3 complex. Cell Host Microbe 12:211-222. http://dx.doi.org/10.1016/j.chom.2012.06.009.
39. BernM,Cai Y, Goldberg D. 2007. Lookup peaks: a hybrid of de novo sequencing and database search for protein identification by tandem mass spectrometry. Anal. Chem. 79:1393-1400. http://dx.doi.org/10.1021/ac0617013.
40. Burgess A, Vigneron S, Brioudes E, Labbe JC, Lorca T, Castro A. 2010. Loss of human Greatwall results in G2 arrest and multiple mitotic defects due to deregulation of the cyclin B-Cdc2/PP2A balance. Proc. Natl. Acad. Sci. U. S. A. 107: 12564-12569. http://dx.doi.org/10.1073/pnas.0914191107.
41. New M, Olzscha H, La Thangue NB. 2012. HDAC inhibitor-based therapies: can we interpret the code? Mol. Oncol. 6:637-656. http://dx.doi .org/10.1016/j.molonc.2012.09.003.
42. Greene WC, Chen LF. 2004. Regulation of NF-kappaB action by reversible acetylation. Novartis Found. Symp. 259:208-225. http://dx.doi.org/10.1002/0470862637.ch15.
43. Chen LF, Mu Y, Greene WC. 2002. Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB. EMBO J. 21:6539-6548. http://dx.doi.org/10.1093/emboj/cdf660.
44. Lee J, Rhee MH, Kim E, Cho JY. 2012. BAY 11-7082 is a broad-spectrum inhibitor with anti-inflammatory activity against multiple targets. Mediators Inflamm. 2012:416036. http://dx.doi.org/10.1155/2012/416036.
45. Safran M, Dalah I, Alexander J, Rosen N, Iny Stein T, Shmoish M, Nativ N, Bahir I, Doniger T, Krug H, Sirota-Madi A, Olender T, Golan Y, Stelzer G, Harel A, Lancet D. 2010. GeneCards Version 3: the human gene integrator. Database 2010:baq020. http://dx.doi.org/10.1093/database/baq020.
46. Chan LL, Shen D, Wilkinson AR, Patton W, Lai N, Chan E, Kuksin D, Lin B, Qiu J. 2012. A novel image-based cytometry method for autophagy detection in living cells. Autophagy 8:1371-1382. http://dx.doi.org/10 .4161/auto.21028.
47. Richetta C, Faure M. 2013. Autophagy in antiviral innate immunity. Cell Microbiol. 15:368-376. http://dx.doi.org/10.1111/cmi.12043.
48. Klionsky DJ, Baehrecke EH, Brumell JH, Chu CT, Codogno P, Cuervo AM, Cuervo AM, Debnath J, Deretic V, Elazar Z, Eskelinen EL, Fin-Beiner S, Fueyo-Margareto J, Gewirtz D, Jäättelä M, Kroemer G, Levine B, Melia TJ, Mizushima N, Rubinsztein DC, Simonsen A, Thorburn A, Thumm M, Tooze SA. 2011. A comprehensive glossary of autophagyrelated molecules and processes (2nd edition). Autophagy 7:1273-1294. http://dx.doi.org/10.4161/auto.7.11.17661.
49. Alvarez-Breckenridge CA, Yu J, Price R, Wei M, Wang Y, Nowicki MO, Ha YP, Bergin S, Hwang C, Fernandez SA, Kaur B, Caligiuri MA, Chiocca EA. 2012. The histone deacetylase inhibitor valproic acid lessens NK cell action against oncolytic virus-infected glioblastoma cells by inhibition of STAT5/T-BET signaling and generation of gamma interferon. J. Virol. 86:4566-4577. http://dx.doi.org/10.1128/JVI.05545-11.
50. MacTavish H, Diallo JS, Huang B, Stanford M, Le Boeuf F, De Silva N, Cox J, Simmons JG, Guimond T, Falls T, McCart JA, Atkins H, Breitbach C, Kirn D, Thorne S, Bell JC. 2010. Enhancement of vaccinia virus based oncolysis with histone deacetylase inhibitors. PLoS One 5:e14462. http://dx.doi.org/10.1371/journal.pone.0014462.
51. Watanabe T, Hioki M, Fujiwara T, Nishizaki M, Kagawa S, Taki M, Kishimoto H, Endo Y, Urata Y, Tanaka N, Fujiwara T. 2006. Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells. Exp. Cell Res. 312:256-265. http://dx.doi.org/10.1016/j .yexcr.2005.10.026.
52. Buerki C, Rothgiesser KM, Valovka T, Owen HR, Rehrauer H, Fey M, Lane WS, Hottiger MO. 2008. Functional relevance of novel p300-mediated lysine 314 and 315 acetylation of RelA/p65. Nucleic Acids Res. 36:1665-1680. http://dx.doi.org/10.1093/nar/gkn003.
53. Kiernan R, Bres V, Ng RW, Coudart MP, El Messaoudi S, Sardet C, Jin DY, Emiliani S, Benkirane M. 2003. Post-activation turn-off of NFkappa B-dependent transcription is regulated by acetylation of p65. J. Biol. Chem. 278:2758-2766. http://dx.doi.org/10.1074/jbc.M209572200.
54. Alonso MM, Jiang H, Yokoyama T, Xu J, Bekele NB, Lang FF, Kondo S, Gomez-Manzano C, Fueyo J. 2008. Delta-24-RGD in combination with RAD001 induces enhanced anti-glioma effect via autophagic cell death. Mol. Ther. 16:487-493. http://dx.doi.org/10.1038/sj.mt.6300400.
55. Samuel S, Beljanski V, Van Grevenynghe J, Richards S, Ben Yebdri F, He Z, Nichols C, Belgnaoui SM, Steel C, Goulet ML, Shamy A, Brown D, Abesada G, Haddad EK, Hiscott J. 2013. BCL-2 inhibitors sensitize therapy-resistant chronic lymphocytic leukemia cells to VSV oncolysis. Mol. Ther. 21:1413-1423. http://dx.doi.org/10.1038/mt.2013.91.
56. Niso-Santano M, Criollo A, Malik SA, Michaud M, Morselli E, Marino G, Lachkar S, Galluzzi L, Maiuri MC, Kroemer G. 2012. Direct molecular interactions between Beclin 1 and the canonical NFkappaB activation pathway. Autophagy 8:268-270. http://dx.doi.org/10.4161/auto.8.2.18845.
57. Hiscott J, Nguyen TL, Arguello M, Nakhaei P, Paz S. 2006. Manipulation of the nuclear factor-kappaB pathway and the innate immune response by viruses. Oncogene 25:6844-6867. http://dx.doi.org/10.1038/sj .onc.1209941.
58. Shrivastava S, Raychoudhuri A, Steele R, Ray R, Ray RB. 2011. Knockdown of autophagy enhances the innate immune response in hepatitis C virus-infected hepatocytes. Hepatology 53:406-414. http://dx.doi.org/10 .1002/hep.24073.
59. Jounai N, Takeshita F, Kobiyama K, Sawano A, Miyawaki A, Xin KQ, Ishii KJ, Kawai T, Akira S, Suzuki K, Okuda K. 2007. The Atg5 Atg12 conjugate associates with innate antiviral immune responses. Proc. Natl. Acad. Sci. U. S. A. 104:14050-14055. http://dx.doi.org/10.1073/pnas .0704014104.
60. Patel MR, Kratzke RA. 2013. Oncolytic virus therapy for cancer: the first wave of translational clinical trials. Transl. Res. 161:355-364. http://dx.doi .org/10.1016/j.trsl.2012.12.010.